Xencor Beats Earnings Expectations, Falls Short on Revenue
Update: 2025-11-05
Description
Xencor's Q3 Financials: A Mixed Bag of Surprises - Despite a net loss of $6 million, Xencor outperformed expectations with earnings per share, thanks to better-than-anticipated expenses. However, revenue fell short of forecasts, with sales at $21 million, missing the predicted $25.7 million. The biotech firm, known for its work on antibodies for autoimmune, allergic, and cancer treatments, faces the typical challenges of high R&D costs and unpredictable revenue in the sector.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
